185 related articles for article (PubMed ID: 35644019)
1. Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.
Guan H; Wang C; Zhao Z; Han S
Adv Ther; 2022 Jul; 39(7):3334-3346. PubMed ID: 35644019
[TBL] [Abstract][Full Text] [Related]
2. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
Meng R; Cao Y; Zhou T; Hu H; Qiu Y
Front Public Health; 2022; 10():794131. PubMed ID: 35433574
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Meng R; Zhang X; Zhou T; Luo M; Qiu Y
Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1079-1086. PubMed ID: 35579405
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
Zhao M; Pan X; Yin Y; Hu H; Wei J; Bai Z; Tang W
Front Public Health; 2022; 10():869960. PubMed ID: 35493395
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Shu Y; Tang Y; Ding Y; Zhang Q
Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
10. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Wang L; Peng Y; Qin S; Wan X; Zeng X; Li S; Liu Q; Tan C
PLoS One; 2023; 18(4):e0279786. PubMed ID: 37053300
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
Gong H; Ong SC; Li F; Weng Z; Zhao K; Jiang Z
Cost Eff Resour Alloc; 2023 Mar; 21(1):20. PubMed ID: 37004046
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
Li W; Wan L
BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Cai H; Zhang L; Li N; Zheng B; Liu M
J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
Lang W; Deng L; Huang B; Zhong D; Zhang G; Lu M; Ouyang M
Clin Drug Investig; 2024 Mar; 44(3):149-162. PubMed ID: 38300386
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Kim JJ; McFarlane T; Tully S; Wong WWL
Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
[TBL] [Abstract][Full Text] [Related]
19. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S; Bi F; Gu S; Bai Y; Chen Z; Wang Z; Ying J; Lu Y; Meng Z; Pan H; Yang P; Zhang H; Chen X; Xu A; Cui C; Zhu B; Wu J; Xin X; Wang J; Shan J; Chen J; Zheng Z; Xu L; Wen X; You Z; Ren Z; Liu X; Qiu M; Wu L; Chen F
J Clin Oncol; 2021 Sep; 39(27):3002-3011. PubMed ID: 34185551
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
